Applied Biosystems and TGen will collaborate on translational genomic disease studies employing the SOLiD 3 system. The partners also hope to drive down the cost of genome sequencing so that it can ultimately be used as a routine diagnostic tool.
HHMI and University of Washington researcher Evan Eichler led a team of researchers who found evidence suggesting a gene called IRGM became a pseudogene in the ancestor of monkeys and apes before being resurrected in the human-great ape lineage.
NHLBI in late January put out an RFP for the program, which calls for researchers to develop proteomics technologies and apply them to solve clinical puzzles. It is set to begin early next year, shortly after its current two major proteomics initiatives expire.
Researchers from the University of Cambridge and Roche 454 Life Sciences who used re-sequencing to evaluate genes from previous type 1 diabetes GWAS have found several protective variants in a gene called IFIH1.
If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the institute, which hopes to diversify its revenue sources once cash from sole corporate sponsor Kirin Pharma USA dries up in 2010.
Sylentis will perform the initial clinical trial on its own in Spain for logistical reasons, but expects to later test the topically administered drug in other countries, including the US, according to a company official.
Based on their assessment of SNP data for several complex diseases, researchers from the University of Pittsburgh and the University of California at Los Angeles warn that genetic tests based on existing GWAS may not be refined enough to accurately predict individual disease risk.
Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.